All In Biotech

NDA 018896 · Hospira

Potassium Acetate

Potassium Acetate · Injection

Last checked: Nov 20, 2026Latest source record: Jun 12, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Jul 20, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

16

4 Phase 3, 0 recruiting

FAERS reports

1,458

1,056 serious, 160 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 27, 2026.

INDICATIONS AND USAGE Potassium Acetate Injection, USP (2 mEq/mL) is indicated as a source of potassium, for the addition to large volume intravenous fluids, to prevent or correct hypokalemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 20, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • POTASSIUM ACETATE · POTASSIUM ACETATE 2MEQ/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Potassium Acetate" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea109
  • diarrhoea108
  • nausea108
  • fatigue103
  • asthenia85
  • dizziness84
  • drug ineffective84
  • headache61
  • weight decreased60
  • death57
  • pain57
  • vomiting57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200590
2006242
2007424
20082
20094
20104
201175
201296
201312
20148
201517
201639
201731
201856
201962
202055
202134
202238
202326
202442
202534
202659

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Potassium Acetate (Potassium Acetate)

2024 spending

$2K

Beneficiaries

n/a

48 claims

Per beneficiary

n/a

$0.29 per unit

View as table
YearSpending
2020$12,383
2021$9,063
2022$734
2023$2,555
2024$2,499

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.